Atlas Venture — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Reza Halse(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $40M raise · filed Jul 2021
Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.
BiotechHealthtechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Peter Dudek(Director)David Grayzel(Director)Nancy Hong(Director)Rachel Humphrey(Director)
Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021
BiotechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)Michael Gladstone(Director)Derek DiRocco(Director)Julie Papanek Grant(Director)John Josey(Director)Natalie Holles(Director)
Board seatMichael Gladstone· per SEC Form D · $130M raise · filed Feb 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.